etidronate has been researched along with Amyotrophic Lateral Sclerosis in 2 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, G | 1 |
| Nakayama, L | 1 |
| Blum, JA | 1 |
| Akiyama, T | 1 |
| Boeynaems, S | 1 |
| Chakraborty, M | 1 |
| Couthouis, J | 1 |
| Tassoni-Tsuchida, E | 1 |
| Rodriguez, CM | 1 |
| Bassik, MC | 1 |
| Gitler, AD | 1 |
| Sato, Y | 1 |
| Honda, Y | 1 |
| Iwamoto, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Late[NCT04494256] | Phase 1/Phase 2 | 99 participants (Actual) | Interventional | 2020-09-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for etidronate and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
RETRACTED: Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial.
Topics: Abdominal Pain; Aged; Amyotrophic Lateral Sclerosis; Bone Density; Bone Density Conservation Agents; | 2006 |
1 other study available for etidronate and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2.
Topics: Amyotrophic Lateral Sclerosis; Animals; Ataxin-2; Etidronic Acid; Humans; Mice; Oligonucleotides, An | 2022 |